Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Famous Restroom Beautifying Styles For 2024 - 2The Extraordinary Excursion of Dental Embed Innovation
- 3One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- 4OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- 5Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
- The Best Portable Applications for Psychological wellness and Prosperity
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Public Parks in the USA
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- The most effective method to Decisively Use Open Record Rewards
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- From Exemplary to Current: Famous Rings Available
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
